Haisco licenses inflammatory disease drug to Sentivera; ViiV's HIV drug cleared for newborns
Haisco Pharmaceutical has granted US startup Sentivera ex-China rights to an unnamed inflammatory disease drug. Separately, ViiV Healthcare's HIV treatment has received approval for use in newborns. The two developments mark progress in different therapeutic areas.
Related stories
FDA grants accelerated approval to Bristol Myers Squibb's iberdomide for relapsed multiple myeloma · Cancer research
FDA clears Revolution Medicines' daraxonrasib for pancreatic cancer · Cancer research
TwinStrand wins patent lawsuit, GSK's hepatitis B drug gains Japan approval · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Haisco grants license to Sentivera; ViiV's HIV treatment OK'd for newborns.” Browse more stories.